Personalized & Precise
Next generation cancer-targeted radiopharmaceuticals
Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.
Monopar's team is located in San Francisco, CA and Chicago, IL.
Monopar is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers.
Monopar recently in-licensed bis-choline tetrathiomolybdate (ALXN1840), a late-stage investigational drug to treat Wilson Disease.
Monopar's pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac.
Product | Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|---|
MNPR‑101‑Zr (Oncology) |
Advanced Solid Cancers (Imaging) |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Phase 1 Clinical Trial Active and Recruiting |
MNPR-101-Lu (Oncology) |
Advanced Solid Cancers |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Phase 1a Clinical Trial Active and Recruiting |
MNPR-101-Ac (Oncology) |
Advanced Solid Cancers |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Late Preclinical |
Early Pipeline (Oncology) |
Solid cancers |
Discovery complete |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Early Preclinical |
Early Pipeline (Oncology) |
Solid cancers |
Discovery in progress |
Preclinical not started |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Discovery |
ALXN1840 (Rare Disease) |
Wilson Disease |
Discovery complete |
Preclinical complete |
Phase 1 complete |
Phase 2 complete |
Phase 3 in progress |
Phase 3 - Primary Endpoint Met Phase 2 - MOA Inconclusive, Endpoints Not Met |